State of the art of lipid apheresis

Artificial Organs

Volumn 20, Issue 4, 1996, Pages 292-295

  Bosch, Thomas ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Dextran sulfate; Double filtration; Heparin induced LDL precipitation; Immunoadsorption; LDL hemoperfusion; Lipid apheresis; Lipoprotein (a); Low density lipoprotein cholesterol; Plasma exchange

Indexed keywords

DEXTRAN; LIPOPROTEINS; PATIENT TREATMENT; SODIUM DODECYL SULFATE;

DEXTRAN SULPHATE; DOUBLE FILTRATION; HEMOPERFUSION; HEPARIN-INDUCED LOW-DENSITY LIPOPROTEIN PRECIPITATION; IMMUNOADSORPTION; LIPID APHERESIS; LIPOPROTEIN (A); LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEINS; LOW-DENSITY LIPOPROTEIN CHOLESTEROL; LOW-DENSITY LIPOPROTEIN HEMOPERFUSION; PLASMA EXCHANGES;

SULFUR COMPOUNDS;

HEPARIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

APHERESIS; HEMOPERFUSION; HUMAN; HYPOCHOLESTEROLEMIA; IMMUNOADSORPTION; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0029984122     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1594.1996.tb04447.x     Document Type: Short Survey

References (22)

1. Thompson GR. Progression and regression of coronary artery disease. Curr Opin Lipidol 1992;3:263-7.
2. Bosch T, Seidel D, Gurland HJ. Efficacy of lipid apheresis: definitions and influencing factors. Int J Artif Organs 1995; 18:210-5.
3. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 1995;332:512-21.
4. Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolemia. Lancet 1975;1:1208-11.
5. Tanaka M, Nohara R, Yohode Y, Tsuyuguchi N, Suwo M, Doi T, Kanatsu K, Nagai H. Double-filtration plasmapheresis for a homozygous familial hypercholesterolemia. In: Oda T, ed. Therapeutic plasmapheresis (II). Schattauer Verlag, 1982:315-8
6. Nosé Y, Usami M, Malchesky PS, Emura M, Horiuchi T. Clinical thermofiltration: initial application. Artif Organs 1985;9:425-7.
7. Kochinke F, von Baeyer H, Schwaner I, Schwerdtfeger R. Comparison of plasma fractionation filters and filtration techniques in the clinical practice of LDL-apheresis. Trans Am Soc Artif Organs 1986;32:388-91.
8. Matsuda Y, Sueoka A, Nosé Y. An effective LDL removal filter for the treatment of hyperlipidemia. Artif Organs 1995; 19:129-34.
9. Borberg H, Gaczkowski A, Hombach V, Oette K, Stoffel W. Treatment of familial hypercholesterolemia by means of specific immunoadsorption. J Clin Apheresis 1988;4:59-65.
10. Richter WO, Sühler K, Schwandt P. Extracorporeal LDL elimination by immunoadsorption: side effects and influences on other serum lipoproteins and serum parameters. In: Gotto AM, Mancini M, Richter WO, Schwandt P, eds. Treatment of severe hypercholesterolemia in the prevention of coronary heart disease. 2nd ed. Basel: Karger, 1990: 183-7.
11. Yokoyama S, Hayashi R, Satani M, Yamamoto A. Selective removal of LDL by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis 1985;5:613-22.
12. Bosch T, Blumenstein M, Dendorfer U, Samtleben W, Schmidt B, Gurland HJ. Klinische LDL-Adsorption an Dextransulfat mit automatischer on-line Adsorberregeneration bei Hyperlipoproteinämie. In: Gurland HJ, Koch KM, Schoeppe W, Scigalla P, eds. Innovative Aspekte der klinischen Medizin. 1st ed. Berlin: Springer Verlag, 1989:38-51.
13. Bosch T, Schmidt B, Samtleben W, Gurland HJ. New LDL adsorption column containing dextran sulfate: ex vivo clinical performance and biocompatibility. In: Oda T, Shiokawa Y, Inoue N, eds. Therapeutic plasmapheresis (VI). Cleveland: ISAO Press, 1987:576-80.
14. Olbricht CJ, Schaumann D, Fischer D. Anaphylactoid reactions, LDL apheresis with dextran sulfate, and ACE inhibitors. Lancet 1992;340:908-9.
15. Eisenhauer T, Armstrong VW, Wieland H, Fuchs C, Scheler F, Seidel D. Selective removal of low density lipoprotein by precipitation at low pH: first clinical application of the HELP system. Klin Wochenschr 1987;65:161-8.
16. Bosch T, Thiery J, Gurland HJ, Seidel D. Long-term efficiency, biocompatibility, and clinical safety of combined simultaneous LDL-apheresis and haemodialysis in patients with hypercholesterolaemia and end-stage renal failure. Nephrol Dial Transplant 1993;8:1350-8.
17. Hombach V, Borberg H, Gadzkowski A, Oette K, Stoffel W. Regression der Koronarsklerose bei familiärer Hypercholesterinämie IIa durch spezifische LDL-Apherese. Dtsch Med Wochenschr 1986;111:1709-15.
18. Tatami R, Inoue N, Itoh H, Kishino B, Koga N, Nakashima Y. Regression of coronary atherosclerosis by combined LDL apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. Atherosclerosis 1992;95:1-13.
19. Schuff-Werner P, Gohlke H, Bartmann U, Baggio G, Corti MC. The HELP-STUDY group. The HELP-LDL-apheresis multicenter study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. Eur J Clin Invest 1994;24:724-32.
20. Pokrovsky SN, Sussekov AV, Afanasieva OY, Adamova IY, Lyashikev AA, Kukharchuk W. Extracorporeal immunoadsorption for the specific removal of lipoprotein(a) (Lp[a] apheresis): preliminary clinical data. Chem Phys Lipids 1994;67/68:323-30.
21. Bosch T, Schmidt B, Blumenstein M, Gurland HJ. Lipid apheresis by hemoperfusion: in vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood. Artif Organs 1993;17: 640-52.
22. Bosch T, Schmidt B, Kleophas W, Tersleegen B, Leschke M, Otto V, Passlick-Deetjen J, Gurland HJ. Clinical efficacy and biocompatibility of the first LDL-adsorber compatible with human whole blood. Int J Artif Organs 1995;18:417.